Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Editas Medicine Appoints Baisong Mei, M.D., Ph.D., as Chief Medical Officer
11:00am, Monday, 18'th Jul 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the appointment of Baisong Mei, M.D., Ph.D., as the Compan
The 3 Leaders of the Gene Editing Revolution
04:12pm, Friday, 08'th Jul 2022
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. The post The 3 Leaders of the Gene Editing Revolution appeared f
7 Moonshot Investments Upending a $10 Trillion Industry
03:53pm, Friday, 08'th Jul 2022
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. The post 7 Moonshot Investments Upending a $10 Trillion Industry appeared first on
Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug
03:48pm, Friday, 08'th Jul 2022 Zacks Investment Research
Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.
Why Shares of Bluebird Bio, CRISPR Therapeutics, and Editas Medicine Soared This Week
02:01pm, Friday, 08'th Jul 2022 The Motley Fool
These high-tech biotech stocks made a sharp U-turn this week after a rough start to the year.
3 Lost Formula Stocks to Consider for July
12:34pm, Friday, 08'th Jul 2022
Following a stronger-than-expected jobs report for June, U.S. market indexes rose on Friday as investors anticipate the Federal Reserve will continue with its aggressive interest rate hikes as it atte
Why Shares of Bluebird Bio, CRISPR Therapeutics, and Editas Medicine Soared This Week
10:01am, Friday, 08'th Jul 2022
These high-tech biotech stocks made a sharp U-turn this week after a rough start to the year.
A Comprehensive Guide to Genomic ETFs
05:43pm, Tuesday, 28'th Jun 2022
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
BeiGene, Ltd. (BGNE) Soars 15.5%: Is Further Upside Left in the Stock?
12:10pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
BeiGene, Ltd. (BGNE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down t
Editas Medicine Reports Inducement Grants to New Chief Executive Officer
08:30pm, Monday, 06'th Jun 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly ap
Editas: Tackling Rare Eye Disease With Use Of Crispr Technology
04:54pm, Monday, 06'th Jun 2022
Results from the phase 1/2 BRILLIANCE study using EDIT-101 in patients with LCA10 are expected in the second half of 2022. Editas was the clear winner with respect to Broad winning the patent dispute
Editas (EDIT) Down 20.7% Since Last Earnings Report: Can It Rebound?
03:31pm, Friday, 03'rd Jun 2022 Zacks Investment Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Editas (EDIT) Down 20.7% Since Last Earnings Report: Can It Rebound?
12:49pm, Friday, 03'rd Jun 2022
Editas (EDIT) reported earnings 30 days ago. What's next for the stock?
Cathie Wood Is Selling Gene Editing Stocks. Here's Why.
11:45am, Thursday, 02'nd Jun 2022
Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves?
Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting
10:45am, Wednesday, 18'th May 2022 GlobeNewswire Inc.
SLEEK results in highly efficient multi-transgene knock-in and enables tunability of transgene expression
